{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:31Z","timestamp":1760144191404,"version":"build-2065373602"},"reference-count":103,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Toronto"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>On 15\u201316 June 2023, healthcare professionals and breast cancer patients and advocates from across Canada met in Toronto, Ontario, for the 2023 Canadian Breast Cancer Symposium (CBSC.). The CBSC. is a national, multidisciplinary event that occurs every 2 years with the goal of developing a personalized approach to the management of breast cancer in Canada. Experts provided state-of-the-art information to help optimally manage breast cancer patients, including etiology, prevention, diagnosis, experimental biology, and therapy of breast cancer and premalignant breast disease. The symposium also had the objectives of increasing communication and collaboration among breast cancer healthcare providers nationwide and providing a comprehensive and real-life review of the many facets of breast cancer. The sessions covered the patient voice, the top breast cancer papers from different disciplines in 2022, artificial intelligence in breast cancer, systemic therapy updates, the management of central nervous system metastases, multidisciplinary management of ductal carcinoma in situ, special populations, optimization-based individual prognostic factors, toxicity management of novel therapeutics, survivorship, and updates in surgical oncology. The key takeaways of these sessions have been summarized in this conference report.<\/jats:p>","DOI":"10.3390\/curroncol31040135","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T07:18:28Z","timestamp":1711955908000},"page":"1774-1802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Canadian Breast Cancer Symposium 2023 Meeting Report"],"prefix":"10.3390","volume":"31","author":[{"given":"Tulin","family":"Cil","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Boileau","sequence":"additional","affiliation":[{"name":"Jewish General Hospital, Montreal, QC H3T 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Chia","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Centre, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"DeCoteau","sequence":"additional","affiliation":[{"name":"Rethink Breast Cancer, Toronto, ON M4M 3G3, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Koch","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Nixon","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, University of Calgary, Calgary, AB T2N 4Z6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Lynn","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Surgery and Oncology, University of Calgary, Calgary, AB T2N 4Z6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Roberts","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-318X","authenticated-orcid":false,"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[{"name":"Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","article-title":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","volume":"388","author":"Partridge","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus Endocrine Therapy for Hormone Receptor-Positive, HER2-Negative, Node-Positive, High-Risk Early Breast Cancer (monarchE): Results from a Preplanned Interim Analysis of a Randomised, Open-Label, Phase 3 Trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3747\/co.27.5769","article-title":"A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women","volume":"27","author":"Seung","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab Govitecan in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation Doses and Fractionation Schedules in Non-Low-Risk Ductal Carcinoma in Situ in the Breast (BIG 3-07\/TROG 07.01): A Randomised, Factorial, Multicentre, Open-Label, Phase 3 Study","volume":"400","author":"Chua","year":"2022","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer","volume":"388","author":"Kunkler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.22.00044","article-title":"Internal Mammary Node Irradiation in Patients with Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study","volume":"40","author":"Thorsen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A Phase IIR\/III Trial of Standard of Care Systemic Therapy with or without Stereotactic Body Radiotherapy (SBRT) and\/or Surgical Resection (SR) for Newly Oligometastatic Breast Cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tsai, C.J., Yang, J.T., Guttmann, D.M., Shaverdian, N., Eng, J., Yeh, R., Girshman, J., Das, J., Gelblum, D., and Xu, A.J. (2022). Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers. Int. J. Radiat. Oncol. Biol. Phys., 114.","DOI":"10.1016\/j.ijrobp.2022.09.008"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1200\/JCO.22.02553","article-title":"Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance)","volume":"41","author":"Boughey","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gentilini, O.D., Botteri, E., Sangalli, C., Galimberti, V., Porpiglia, M., Agresti, R., Luini, A., Viale, G., Cassano, E., and Peradze, N. (2023). Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2023.3759"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"GS4-02","DOI":"10.1158\/1538-7445.SABCS22-GS4-02","article-title":"Abstract GS4-02: Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: The OPBC-04\/EUBREAST-06\/OMA Study","volume":"83","author":"Montagna","year":"2023","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.21.02006","article-title":"Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)","volume":"40","author":"Khan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2017.14585","article-title":"Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women with Breast Cancer","volume":"318","author":"Veta","year":"2017","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.1016\/j.modpat.2023.100216","article-title":"Artificial Intelligence-Aided Diagnosis of Breast Cancer Lymph Node Metastasis on Histologic Slides in a Digital Workflow","volume":"36","author":"Challa","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41523-022-00496-w","article-title":"Validation and Real-World Clinical Application of an Artificial Intelligence Algorithm for Breast Cancer Detection in Biopsies","volume":"8","author":"Sandbank","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djad013","article-title":"Use of Artificial Intelligence for Cancer Clinical Trial Enrollment: A Systematic Review and Meta-Analysis","volume":"115","author":"Chow","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and Endocrine Therapy as Adjuvant Treatment in Patients with HR+\/HER2- Early Breast Cancer: Primary Results from the Phase III NATALEE Trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to Fulvestrant and Palbociclib versus No Switch in Advanced Breast Cancer with Rising ESR1 Mutation during Aromatase Inhibitor and Palbociclib Therapy (PADA-1): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy De-Escalation Using an 18F-FDG-PET-Based Pathological Response-Adapted Strategy in Patients with HER2-Positive Early Breast Cancer (PHERGain): A Multicentre, Randomised, Open-Label, Non-Comparative, Phase 2 Trial","volume":"22","author":"Gebhart","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab Deruxtecan versus Treatment of Physician\u2019s Choice in Patients with HER2-Positive Metastatic Breast Cancer (DESTINY-Breast02): A Randomised, Open-Label, Multicentre, Phase 3 Trial","volume":"401","author":"Kim","year":"2023","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/2159-8290.CD-22-0837","article-title":"Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis","volume":"12","author":"Jerusalem","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with Brain Metastases: A Single-Arm, Phase 2 Trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in Patients with Brain Metastases Treated with Radiosurgery or Radiosurgery plus Whole-Brain Irradiation: A Randomised Controlled Trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","article-title":"Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today","volume":"107","author":"Sperduto","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The Impact of Sequencing PD-1\/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-020-03657-8","article-title":"Type and Timing of Systemic Therapy Use Predict Overall Survival for Patients with Brain Metastases Treated with Radiation Therapy","volume":"151","author":"Fan","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial","volume":"38","author":"Lin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial","volume":"25","author":"Cortez","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"PD13-07","DOI":"10.1158\/1538-7445.SABCS20-PD13-07","article-title":"Abstract PD13-07: Subgroup Analysis of Patients with Brain Metastases from the Phase 3 ASCENT Study of Sacituzumab Govitecan versus Chemotherapy in Metastatic Triple-Negative Breast Cancer","volume":"81","author":"Weaver","year":"2021","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Metastatic Breast Cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Patients with Brain Metastasis from Solid Tumours","volume":"32","author":"Guckenberger","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.22.02900","article-title":"Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study","volume":"41","author":"Lazzeroni","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.20.02063","article-title":"Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer","volume":"39","author":"Magnuson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaoncol.2023.0339","article-title":"Long-Term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum","volume":"9","author":"Cairncross","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.breast.2021.04.005","article-title":"Neurocognitive Outcomes Following Fetal Exposure to Chemotherapy for Gestational Breast Cancer: A Canadian Multi-Center Cohort Study","volume":"58","author":"Maxwell","year":"2021","journal-title":"Breast"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2239884","DOI":"10.1001\/jamanetworkopen.2022.39884","article-title":"Participation of Patients From Racial and Ethnic Minority Groups in Phase 1 Early Cancer Drug Development Trials in the US, 2000-2018","volume":"5","author":"Dunlop","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/PAI.0000000000001065","article-title":"The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry","volume":"31","author":"Bhargava","year":"2023","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or Surgery of the Axilla after a Positive Sentinel Node in Breast Cancer (EORTC 10981-22023 AMAROS): A Randomised, Multicentre, Open-Label, Phase 3 Non-Inferiority Trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab Emtansine versus Treatment of Physician\u2019s Choice in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results from a Randomised Open-Label Phase 3 Trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2022.40.16_suppl.1000","article-title":"Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in Patients (Pts) with HER2-Positive (HER2+) Unresectable and\/or Metastatic Breast Cancer (mBC): Safety Follow-up of the Randomized, Phase 3 Study DESTINY-Breast03","volume":"40","author":"Hamilton","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/JCO.2023.41.16_suppl.1003","article-title":"Final Overall Survival (OS) Analysis from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (Pts) with Hormone Receptor\u2013Positive\/HER2-Negative (HR+\/HER2\u2013) Metastatic Breast Cancer (mBC)","volume":"41","author":"Tolaney","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical Outcomes from the Phase 3 CheckMate 816 Trial: Nivolumab (NIVO) + Platinum-Doublet Chemotherapy (Chemo) vs Chemo Alone as Neoadjuvant Treatment for Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"LBA100","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA100","article-title":"KEYNOTE-671: Randomized, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo plus Platinum-Based Chemotherapy Followed by Resection and Pembrolizumab or Placebo for Early Stage NSCLC","volume":"41","author":"Wakelee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_60","first-page":"1459","article-title":"Canadian National Breast Screening Study: 1. Breast Cancer Detection and Death Rates among Women Aged 40 to 49 Years","volume":"147","author":"Miller","year":"1992","journal-title":"CMAJ"},{"key":"ref_61","first-page":"1477","article-title":"Canadian National Breast Screening Study: 2. Breast Cancer Detection and Death Rates among Women Aged 50 to 59 Years","volume":"147","author":"Miller","year":"1992","journal-title":"CMAJ"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.3390\/curroncol29080444","article-title":"The Impact of Organised Screening Programs on Breast Cancer Stage at Diagnosis for Canadian Women Aged 40\u201349 and 50\u201359","volume":"29","author":"Wilkinson","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene Effectively Treats Vulvovaginal Atrophy in Postmenopausal Women: Results from a Pivotal Phase 3 Study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/09513590.2018.1427717","article-title":"Vulvar Vestibular Effects of Ospemifene: A Pilot Study","volume":"34","author":"Murina","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female Sexual Function Improved with Ospemifene in Postmenopausal Women with Vulvar and Vaginal Atrophy: Results of a Randomized, Placebo-Controlled Trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/jwh.2017.6385","article-title":"Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials","volume":"27","author":"Simon","year":"2018","journal-title":"J. Womens Health (Larchmt)"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.neubiorev.2017.10.028","article-title":"Cognitive Impairment in Breast Cancer Survivors Treated with Chemotherapy Depends on Control Group Type and Cognitive Domains Assessed: A Multilevel Meta-Analysis","volume":"83","author":"Bernstein","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neubiorev.2021.08.024","article-title":"Chemo-Brain: An Activation Likelihood Estimation Meta-Analysis of Functional Magnetic Resonance Imaging Studies","volume":"130","author":"Bernstein","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"14063","DOI":"10.1038\/ncomms14063","article-title":"Caloric Restriction Improves Health and Survival of Rhesus Monkeys","volume":"8","author":"Mattison","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/ajcn\/nqaa388","article-title":"Remodeling of the Gut Microbiome during Ramadan-Associated Intermittent Fasting","volume":"113","author":"Su","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2139558","DOI":"10.1001\/jamanetworkopen.2021.39558","article-title":"Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-Analyses of Randomized Clinical Trials","volume":"4","author":"Patikorn","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1148\/radiol.2442051620","article-title":"The Current Status of Breast MR Imaging. Part I. Choice of Technique, Image Interpretation, Diagnostic Accuracy, and Transfer to Clinical Practice","volume":"244","author":"Kuhl","year":"2007","journal-title":"Radiology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.rcl.2016.12.008","article-title":"Breast MR Imaging in Newly Diagnosed Breast Cancer","volume":"55","author":"Gupta","year":"2017","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-013-2656-1","article-title":"Trends and Clinical Implications of Preoperative Breast MRI in Medicare Beneficiaries with Breast Cancer","volume":"141","author":"Killelea","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamaoncol.2015.3018","article-title":"Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study","volume":"1","author":"Arnaout","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1148\/radiol.2333031484","article-title":"Diagnostic Accuracy of Mammography, Clinical Examination, US, and MR Imaging in Preoperative Assessment of Breast Cancer","volume":"233","author":"Berg","year":"2004","journal-title":"Radiology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1148\/radiology.197.3.7480749","article-title":"Breast Tumors: Comparative Accuracy of MR Imaging Relative to Mammography and US for Demonstrating Extent","volume":"197","author":"Boetes","year":"1995","journal-title":"Radiology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1148\/radiol.2017161449","article-title":"Impact of Preoperative Breast MR Imaging and MR-Guided Surgery on Diagnosis and Surgical Outcome of Women with Invasive Breast Cancer with and without DCIS Component","volume":"284","author":"Kuhl","year":"2017","journal-title":"Radiology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1016\/j.clbc.2022.07.007","article-title":"Preoperative MRI for Evaluation of Extent of Disease in IDC Compared to ILC","volume":"22","author":"Carmon","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2007.15.2108","article-title":"Accuracy and Surgical Impact of Magnetic Resonance Imaging in Breast Cancer Staging: Systematic Review and Meta-Analysis in Detection of Multifocal and Multicentric Cancer","volume":"26","author":"Houssami","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1200\/JCO.2008.21.5756","article-title":"Magnetic Resonance Imaging Screening of the Contralateral Breast in Women with Newly Diagnosed Breast Cancer: Systematic Review and Meta-Analysis of Incremental Cancer Detection and Impact on Surgical Management","volume":"27","author":"Brennan","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1148\/radiol.212361","article-title":"Contralateral Breast Screening with Preoperative MRI: Long-Term Outcomes for Newly Diagnosed Breast Cancer","volume":"304","author":"Freitas","year":"2022","journal-title":"Radiology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4048\/jbc.2022.25.e35","article-title":"Breast Magnetic Resonance Imaging for Patients With Newly Diagnosed Breast Cancer: A Review","volume":"25","author":"Kim","year":"2022","journal-title":"J. Breast Cancer"},{"key":"ref_84","unstructured":"(2023, October 30). | Cancer Care Ontario. Available online: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/70786."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(09)62070-5","article-title":"Comparative Effectiveness of MRI in Breast Cancer (COMICE) Trial: A Randomised Controlled Trial","volume":"375","author":"Turnbull","year":"2010","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.19.03257","article-title":"Imaging in Locoregional Management of Breast Cancer","volume":"38","author":"Kuhl","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Rosenkranz, K.M., Ballman, K., McCall, L., Kubicky, C., Cuttino, L., Le-Petross, H., Hunt, K.K., Giuliano, A., Van Zee, K.J., and Haffty, B. (Ann. Surg. Oncol., 2018). The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial, Ann. Surg. Oncol.","DOI":"10.1245\/s10434-018-6583-6"},{"key":"ref_88","unstructured":"German Society of Gynecologic Oncology (2023, October 31). Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. Version 2023.1E. Available online: https:\/\/www.ago-online.de\/fileadmin\/ago-online\/downloads\/_leitlinien\/kommission_mamma\/2023\/englisch\/Einzeldateien\/AGO_2023E_02_Breast_Cancer_Risk_Genetics_and_Prevention.pdf."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jamcollsurg.2009.04.010","article-title":"Association of Routine Pretreatment Magnetic Resonance Imaging with Time to Surgery, Mastectomy Rate, and Margin Status","volume":"209","author":"Bleicher","year":"2009","journal-title":"J. Am. Coll. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1245\/s10434-014-3748-9","article-title":"Role of Preoperative Magnetic Resonance Imaging in the Surgical Management of Early-Stage Breast Cancer","volume":"21","author":"Chandwani","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Onega, T., Tosteson, A.N.A., Weiss, J., Alford-Teaster, J., Hubbard, R.A., Henderson, L.M., Kerlikowske, K., Goodrich, M.E., O\u2019Donoghue, C., and Wernli, K.J. (2016). Costs of Diagnostic and Preoperative Workup with and without Breast MRI in Older Women with a Breast Cancer Diagnosis. BMC Health Serv. Res., 16.","DOI":"10.1186\/s12913-016-1317-6"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1245\/s10434-019-07345-4","article-title":"A Consensus Definition and Classification System of Oncoplastic Surgery Developed by the American Society of Breast Surgeons","volume":"26","author":"Chatterjee","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/23320885.2021.1986048","article-title":"The Anterior LICAP Flap: A Design Option for Oncoplastic Breast Reconstruction","volume":"8","author":"Jacobs","year":"2021","journal-title":"Case Rep. Plast. Surg. Hand Surg."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/tbj.12356","article-title":"Extreme Oncoplasty: Breast Conservation for Patients Who Need Mastectomy","volume":"21","author":"Silverstein","year":"2015","journal-title":"Breast J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jss.2022.11.067","article-title":"Single Versus Dual Surgeon Approaches to Oncoplastic Surgery: A Comparison of Outcomes","volume":"283","author":"Karamchandani","year":"2023","journal-title":"J. Surg. Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Putri, I.L., Bhandari, L., and Klepetko, H. (2021). Dog-Ear\u2019s Prevention during Inverted-T Breast Lift and Reduction. Ann. Med. Surg., 67.","DOI":"10.1016\/j.amsu.2021.102462"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijsu.2015.12.068","article-title":"Surgical Techniques to Avoid Lateral Dog Ear of the Mastectomy Scar: A Systematic Review","volume":"26","author":"Lim","year":"2016","journal-title":"Int. J. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1245\/s10434-020-09448-9","article-title":"\u201cGoing Flat\u201d After Mastectomy: Patient-Reported Outcomes by Online Survey","volume":"28","author":"Baker","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/tbj.13500","article-title":"Trends in Immediate Breast Reconstruction and Radiation after Mastectomy: A Population Study","volume":"26","author":"Doherty","year":"2020","journal-title":"Breast J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.breast.2022.02.012","article-title":"Exploring Breast Surgeons\u2019 Reasons for Women Not Undergoing Immediate Breast Reconstruction","volume":"63","author":"Matkin","year":"2022","journal-title":"Breast"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10549-018-5018-1","article-title":"Surgical Trends in Breast Cancer: A Rise in Novel Operative Treatment Options over a 12 Year Analysis","volume":"173","author":"Jonczyk","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/tbj.12011","article-title":"Oncoplastic Technique for the Elimination of the Lateral \u201cDog Ear\u201d during Mastectomy","volume":"18","author":"Clough","year":"2012","journal-title":"Breast J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e4116","DOI":"10.1097\/GOX.0000000000004116","article-title":"The Modified M-Plasty Approach to Mastectomy: Avoiding the Lateral Dog-Ear","volume":"10","author":"Meybodi","year":"2022","journal-title":"Plast. Reconstr. Surg. Glob. Open"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/4\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:20:50Z","timestamp":1760106050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/4\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":103,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["curroncol31040135"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31040135","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}